• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Video

Probiotics in atopic dermatitis

Author(s):

Bobby Lazzara, M.D.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease
December 18th 2024

Patients with Atopic Dermatitis Are More Susceptible to Developing Inflammatory Bowel Disease

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older
December 16th 2024

FDA Approves Tapinarof Cream, 1% for Atopic Dermatitis in Patients 2 Years and Older

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

2024 Key Insights: Atopic Dermatitis
December 13th 2024

2024 Key Insights: Atopic Dermatitis

Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors
December 12th 2024

Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors

© 2024 MJH Life Sciences

All rights reserved.